Changes in Hong Kong stocks | Collumbotai Bio-B (06990) rose nearly 3% and established a strategic partnership with Crescent to jointly develop cancer treatments

The Zhitong Finance App learned that Columbotai Bio-B (06990) rose nearly 3%. As of press release, it had risen 2.54% to HK$460.4, and traded HK$674.33,300.

According to the news, on December 4, Columbotai Bio-B announced that the company and Crescent Biopharma, Inc. and its wholly-owned subsidiary Crescent Biopharma Operating Company, LLC (together with Crescent BioPharma, Inc., collectively known as “Crescent” or “Crescent BioPharma”) have established a strategic partnership to jointly develop and commercialize cancer treatment methods (including novel combination therapies) ).

The collaboration involved the company's antibody-conjugated drug (ADC) SKB105 targeting integrin beta-6 (ITGB6) and loaded with a topoisomerase inhibitor, and Crescent, a programmed cell death-1 (PD-1) x vascular endothelial growth factor (VEGF) bispecific antibody (dual antibody) CR-001. Both drug candidates are being developed to treat solid tumors, and phase 1/2 single-agent clinical trials are expected to be conducted in the first quarter of 2026.

Based on this partnership, the company will collect an initial payment of $80 million from Crescent and will be eligible for milestone payments of up to $1.25 billion, as well as tiered royalties based on the medium to low double-digit percentage of SKB105's net sales.